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The production of imaging data in medicine increases more rapidly than the capacity of 
computing models to extract information from it. The grand challenges of better 
understanding the brain, offering better care for neurological disorders, and stimulating new 
drug design will not be achieved without significant advances in computational neuroscience. 
The road to success is to develop a new, generic, computational methodology and to confront 
and validate this methodology on relevant diseases with adapted computational 
infrastructures. This new concept sustains the need to build new research paradigms to better 
understand the natural history of the pathology at the early phase; to better aggregate data 
that will provide the most complete representation of the pathology in order to better correlate 
imaging with other relevant features such as clinical, biological or genetic data. In this 
context, one of the major challenges of neuroimaging in clinical neurosciences is to detect 
quantitative signs of pathological evolution as early as possible to prevent disease 
progression, evaluate therapeutic protocols or even better understand and model the natural 
history of a given neurological pathology. Many diseases encompass brain alterations often 
not visible on conventional MRI sequences, especially in normal appearing brain tissues 
(NABT). MRI has often a low specificity for differentiating between possible pathological 
changes which could help in discriminating between the different pathological stages or 
grades. The objective of medical image analysis procedures is to define new quantitative 
neuroimaging biomarkers to track the evolution of the pathology at different levels. This 
paper illustrates this issue in one acute neuro-inflammatory pathology: Multiple Sclerosis 
(MS). It exhibits the current medical image analysis approaches and explains how this field 
of research will evolve in the next decade to integrate larger scale of information at the 
temporal, cellular, structural and morphological levels.  
1. Introduction 
In medicine, the pace of change in data production is far outstripping the capacity of existing 
computing models. This increase of data stimulates the need to guide the clinicians within 
the mass of information to integrate into the medical decision process. This is acutely 
challenging for brain diseases where the main challenges facing us today include 1) 
increasing our understanding of central nervous system (CNS), 2) undertaking more 
effective monitoring of therapeutic procedures, 3) modeling groups of normal and 
pathological individuals (cohorts) through image descriptors and 4) stimulating new drug 
design. To address these challenges, current practice is missing computational models able 
to correlate the large amount of observations produced on patients to underlying pathological 
phenomena, frameworks to validate these models, and infrastructures to learn these models 
and apply them to large populations of patients. These issues pose new challenges in the field 
of medical image analysis, in terms of developing new integrated computational models of 
living organs and systems capable of mining image descriptors from big databases, 
assimilating the quantity of imaging data produced about a given patient through compact 
and relevant mathematical representations, learning dynamics of spatiotemporal data to 
predict the disease course in individual patients, and reconciling observation and treatment 
processes (the theragnostics concept). Once these major advances will be achieved, the face 
of clinical practice will change both for professionals (innovations in clinical services, 
treatment delivery, training and education) and for citizens (safer, faster and more accurate 
medicine). 
In this paper, we propose to illustrate the relevance of this evolution of the medical image 
analysis domain in one acute neuro-inflammatory pathology: multiple sclerosis (MS). We 
show how computational models have been used in the past to provide some relevant, though 
limited, markers of the disease and its evolution, but also why these existing computational 
solutions are limited and how they will evolve in the next decade in order to tackle the 
remaining challenges and provide imaging biomarkers that become capable of discovering 
quantitative image descriptors that are not necessarily visible to the human eye and use these 
descriptors to better represent the dynamics of the pathology and accurately predict the 
disease course in individual patients. 
 
2. Context: Imaging Biomarkers in Multiple Sclerosis  
MS is a chronic autoimmune demyelinating disorder of the CNS. It is the principal cause of 
severe, non-traumatic disability among young adults, affecting more than half a million 
people in Europe. It has a prevalence rate of 83 per 100,000, and a female:male ratio of nearly 
3:1. Onset usually occurs before the age of 30, that is, at a crucial point in an individual’s 
personal, family, professional and social lives. It leads to permanent disability for decades, 
but has only a marginal effect on life expectancy. MS induces a huge, rapidly increasing, 
financial burden on society, owing to the approval and more widespread use of new disease-
modifying treatments. Disability accumulation in MS is generally acknowledged to be 
correlated with axonal injury, itself being correlated with the degree of inflammation. 
However, the interdependence between inflammation and neuro-degeneration, and their 
respective contributions to clinical deficits remain unclear. Recent epidemiological data from 
our group suggest that MS is a two-stage neurodegenerative inflammatory disease (see 
(Leray et al., 2010). At each stage, the disease progression follows a different 
physiopathological pathway: highly variable in the first stage (EDSS < 3), but broadly similar 
for the whole population in the second stage (EDSS > 3). This new concept highlights the 
need for a better definition of the early stage, starting with the very first event (clinically 
isolated syndrome, CIS), and for new research paradigms to better characterize and monitor 
the progression of the pathology in individual patients. 
 
Figure 1: Epidemiologic study of natural evolution of Multiple Sclerosis disease as a 2-stage course. At onset (time=0), 
a new CIS patient may take from 2 (red) to more than 20 (green) years to reach a clinical score highlighting acute 
handicap (EDSS=3). Why there is such discrepancy in the population, or why a patient will evolve in the “red” group 
or in the “green” one is mostly unknown. Having therapy to move a patient from one group (e.g. red) to another (e.g. 
green) cannot be set up without objective figures to validate this new drug. Imaging is today the only expected 
instrument to respond to these questions since it is mostly non invasive and can potentially be specific and sensitive 






















In recent years, conventional magnetic resonance imaging (MRI) has emerged as a powerful 
noninvasive tool for diagnosis, description of the natural history of the disease and treatment 
monitoring of MS. In addition, MRI findings have been used to explore drug efficacy in 
clinical trials.  
A number of MR studies show that the principal pathological substrate of permanent 
disability is axonal loss, detected in MR studies as global atrophy but also as regional atrophy 
in the white (WM) or grey matter (GM). This atrophy already occurs at early stages of the 
disease. Axons contribute to about 50% of the WM volume and are, together with neurons, 
the main contributors of the GM volume. In early progressive MS, GM atrophy seems to be 
more prominent than WM loss (Dalton et al., 2004; Simon et al., 1999). Longitudinal MR 
studies in CIS patients have demonstrated that early rather than later focal lesion 
accumulation is predictive of conversion from CIS to definite MS, accumulation of clinical 
deficit (Brex et al., 2002; O'Riordan et al., 1998), but also of subsequent brain atrophy. 
Today, it is not possible to determine exactly when atrophy begins even though it is 
detectable in CIS cohorts and in early MS patients. Such a knowledge would be important 
not only for prognostic issues per se, but also crucial to select patients at risk for a severe 
disease course and to start treatment with disease modifying drugs as early as possible. The 
need for robust predictive imaging disease markers in MS at presentation is demonstrated by 
the findings of Brex and colleagues (Brex et al., 2002): after a mean follow-up of about 14 
years of CIS patients, about 12% with four or more focal T2-weighted MR lesions did not 
develop clinically definite MS (CDMS), and thereof only about 40% were only mildly 
disabled. In the CIS group with one to three focal MR lesions at presentation about one third 
develops moderate to severe disability after 14 years follow-up. About 90% of CIS patients 
with one to three MR lesions at presentation develop CDMS 14 years later. Furthermore, 
using conventional MR methodology in clinical trials of CIS patients, a high proportion of 
treated patients continue to have MRI activity. MRI measures of inflammation in Relapsing 
Remitting MS (RRMS) or Secondary Progressive MS (SPMS), such as Gd-enhancement, do 
not correlate with clinical disability at 1 to 2 years follow-up (Kappos et al., 1999). In 
conventional MRI studies, Gadolinium enhancement (Gd-DTPA) reflects a severe focal 
breakdown of the blood-brain barrier (BBB) but this breakdown does not really predict the 
severity of the pathology evolution. 
 
These different studies show that conventional MRI surrogates provide information at the 
macroscopic level but lack sensitivity and specificity in identifying the full extent of 
underlying MS pathology. They also show relatively weak relationships to clinical status 
such as predictive strength for clinical change (called the clinical-MRI paradox) (Barkhof, 
2002). With the advent of disease modifying drugs, there is a need for robust and specific 
MR markers to characterize the pathology especially at onset where patients have high risk 
to develop MS or a more severe disease course. 
The "clinical-MRI paradox" is defined as the absence of correlation between clinical 
disability, and the predictive value of MRI in MS. This paradox prohibits the use of imaging 
as a primary outcome parameter in certification of new drugs. It is assumed that this paradox 
could be partly due to the lack of MRI specificity related to the heterogeneous pathological 
substrates of MS and to its inability to quantify the extent of damage in the normal-appearing 
brain tissues (NABT), i.e. the invisible pathology. It is then expected that non-conventional 
MRI techniques, such as Magnetization Transfer MRI (MTI), Relaxometry, Diffusion 
Tensor Imaging (DTI), Chemical Shift Imaging (CSI), will be able to alleviate these 
limitations by providing information about structural and biochemical changes occurring 
within and outside MS lesions, in particular in the NABT. These techniques could also 
significantly improve the monitoring of the inflammatory demyelination and the axonal loss 
(Bakshi et al., 2008). 
Current medical image analysis methods addressing this issue have still a very limited scope, 
especially in their ability to assimilate a large amount and large variety of information. 
Current data processing technologies focus mostly on pre-processing of conventional MRI, 
especially on data fusion (registration between modalities, patients and atlases), on 
multimodal cross sectional image segmentation or longitudinal MRI intensity evolution of 
macroscopic lesions (usually up to 3 MRI sequences), on estimation of regional and global 
deformations to exhibit atrophy, and on coarse differential detection of diffuse pathology 
from diffusion MRI (mostly performed on scalar maps). Current data processing strategies 
still remain limited to overcome all the limitations of MRI in MS. As such, the methods still 
work on a very limited variety of images able to measure the real early process, and rather 
address later or non-specific pathological stages. The current image processing methods 
assimilate a large but still limited amount of information; they are barely addressing the issue 
of compact feature selection and representation; or barely addressing the issue of learning 
spatio-temporal disease pattern models. Finally, they are not addressing the issue of 
generalization of disease model to derive individual tests and provide prospective figures for 
individual patient follow-up (Crimi et al., 2014).  
To summarize, the advent of disease-modifying drugs has created the need for robust and 
specific imaging markers to characterize the pathology of MS patients and thus identify those 
with a high risk of developing a more severe disease course at onset. 
3. Image processing in Multiple Sclerosis 
3.1. Context 
Today, measures from MRI complement and enrich the clinical observations based on scales 
such as the expanded disability status scale (EDSS) or the MS functional composite (MSFC) 
whose drawbacks are numerous. Clinical observations are inherently subjective, show poor 
inter- and intra-observer reliability, have limited sensitivity to change compared with MRI 
(up to 15 times more sensitive in longitudinal studies). MRI is currently used for assessing 
the disease burden and progression by counting the number of T2w MRI lesions, and the 
number of lesions on gadolinium-enhanced T1w MRI. In this context, a large set of medical 
image processing methods have been developed in recent years to address these issues. 
3.2. Image processing in MS 
Current computer assisted analysis of MR images in MS requires the application of complex 
image processing workflows. These workflows usually encompass standard pre-processing 
stages such as noise removal, non-uniformity intensity correction, intensity normalization, 
spatial normalization, skull-stripping which removes non brain tissues from the image and 
focal WM and GM lesion segmentation. Among this workflow, noise reduction is necessary 
as image intensities are corrupted by additive noise that must be limited to improve the 
signal-to-noise ratio. In general, image noise comes from MR hardware (RF coil, or pre-
amplifier, and MR sequence optimization). Numerous methods for image denoising have 
been proposed in general image processing, reviewed in (Buades et al., 2005). A new 
denoising algorithm, non-local means (NLM), has been proposed by (Coupe et al., 2008) for 
different medical image acquisition techniques and more specifically for MRI, 
demonstrating a clear impact in processing MRI in MS. Another image artefact correction 
concerns the intensity inhomogeneity correction. Vovk et al and Hou (Hou, 2006; Vovk et 
al., 2007) recently reviewed various inhomogeneity correction methods. In principle, these 
artefacts are due to image instrumentation and related to artefacts caused by slow, non-
anatomic intensity variations of the same tissue over an image domain. If left uncorrected, 
such an artefact precludes direct comparison of voxel intensities. Spatial normalization 
concerns the issue of gathering into the same geometric referential system all images that are 
used by the processing workflow. Numerous methods have been proposed in this very active 
field of research (Maintz and Viergever, 1998). Intensity normalization is another processing 
needed that is particularly acute when the frequency of the acquisitions is in the range of 
months or years (Karpate et al., 2014). Finally, skull stripping/brain extraction is usually 
performed in order to ease MS lesions segmentation, in order to remove non-brain tissues 
from the images, see for instance (Fennema-Notestine et al., 2006; Iglesias et al., 2011) for 
a large review and comparison of these methods. 
The last stage of the image processing workflows concerns the detection and segmentation 
of MS lesions (MSL) from brain magnetic resonance images (MRI). Automatic MSL 
detection and recognition is a topic of still growing importance and still challenging. 
Although manual lesion detection by experts is still considered as a Gold Standard, which is 
quite questionable because of the very large discrepancy existing between experts, the 
objective evaluation of lesions becomes difficult for the radiologist when the number and the 
resolution of MRI sequences get larger.  
Macroscopic MS lesions segmentation is performed on multimodal cross-sectional images. 
These segmentation methods can be classified according to the level of interaction needed 
for lesion delineation and the nature and number of MRI sequences used (usually up to 3), 
see (Lladó et al., 2012) for a recent review. A further distinction can be made between data-
driven methods and supervised learning methods. One breed of unsupervised MSL 
segmentation includes Gaussian Mixture Modeling (GMM) on multispectral MRI, where 
each multivariate Gaussian probability density function represents a normal appearing brain 
tissue (Van Leemput et al., 2001). The GMM enables characterization of the image 
intensities with a reduced number of parameters, which are estimated by a maximum 
likelihood estimator (MLE). An effective approach in this domain is to consider MS lesions 
as outliers from NABT (Garcia-Lorenzo et al., 2011; Van Leemput et al., 2001). Supervised 
methods (often related to Machine Learning) require images that have already been 
segmented in order to "learn" how to segment the lesions. Examples in this field are spatial 
decision forests (Geremia et al., 2011), one-class SVM (Karpate et al., 2015a), sparse 
dictionary learning (Deshpande et al., 2015) or deep learning (Brosch et al., 2016). 
Frameworks for segmentation of gadolinium-enhancing lesions were also developed for 
instance through robust statistics on image intensities (Karpate et al., 2015b) or probabilistic 
methods using conditional random fields (Karimaghaloo et al., 2012).  
Integration of these MS lesion patterns into a computational decision making process is still 
rare. Recent advances have been proposed to correlate the inflammatory patterns of MS 
lesions with the risk of evolution of the pathology by using enhanced patterns coming from 
both Gadolinium and a new contrast agent (USPIO) marking early attacks of macrophages 
responsible to the advent of lesions (see Figure 3). Thanks to these approaches, it has been 
demonstrated that patients at onset having specific early patterns of inflammatory lesions 
were correlated with a higher lesion load later in the disease progression, therefore having a 
higher risk of developing a severe course of the disease (Crimi et al., 2014). 
3.3. Image processing of non-conventional MRI 
Quantitative imaging in MS (qMRI) techniques, including diffusion tensor imaging (DTI), 
magnetization transfer imaging (MTI), relaxometry and MR spectroscopy, though not used 
yet in the clinics, have been found to provide useful information about the extent of the 
diffuse tissue injuries (outside lesions) observed in MS patients in both stages of the disease, 
thereby contributing to our understanding of its pathophysiology (Bakshi et al., 2008; Miller, 
2004). For example, DTI studies illustrate an increase in mean diffusivity (MD) and a 
decrease in fractional anisotropy (FA), while MTI shows a decrease in MT ratio in MS 
patients related to both demyelination and axonal loss, particularly in lesion regions but also 
in normal-appearing WM (NAWM) and GM. These studies often require control participants 
with whom patients can be compared. For DTI, scalar measures may lose some of the 
information contained in the diffusion tensors, but it has been shown recently that using the 
whole tensor can improve the detection power in MS. Registration of new diffusion models 
Figure 2: Sample image signature of a lesion from the protocol, images (and day) from left to right: T1-w 
(D1), T1-Gd (D1), T1-w USPIO (D2), T1 relaxometry (D1), T1 relaxometry with USPIO (D2). 
(including multiple compartments) was also devised for the robust detection of patient to 
population differences with small databases using non local approaches. This work allowed 
obtaining meaningful detections of differences in multiple sclerosis, with a similar precision 
as with large control databases (Commowick et al., 2008; Commowick et al., 2015). In 
addition, merging all these complementary parameters derived from different modalities 
(e.g., DTI, MTI ratio maps and relaxometry) is still very challenging, owing to the variations 
in their spatial resolution and artefact sensitivity (Soustelle et al., 2015). There is still a need 
for significant research efforts to integrate the microstructural quantitative MR information 
in a common template. 
Metabolic and hemodynamic characterization of compartments in MS: Whereas 
spectroscopic proton imaging (or chemical shift imaging - CSI) has become a useful clinical 
tool for characterizing metabolic disorders or grading tumors, processing CSI data along with 
complementary qMRI data is still a challenge in MS, as none of the processing packages that 
are currently available provide the entire set of modules required for such a project. 
Similarly, while some preliminary studies have shown that local WM and GM perfusion 
defects can be a precursor of pathology progression in MS, none of the current data analysis 
frameworks are capable of integrating and processing such functional and metabolic 
recordings with qMRI, let alone with cell-specific imaging. 
4. Perspectives : How to go beyond the clinical-MRI paradox? 
Current medical image analysis methods are mostly directed towards the detection of what 
is visible to the human eye. New image processing mechanisms need to be introduced in 
order to quantify the pathology even if the defects are not directly visible. Data-processing 
strategies remain too limited to overcome the medical imaging challenge in MS. Existing 
methods work on a very limited number of observations and patients, they assimilate a large, 
but still limited amount of information. They fail at addressing the issues of compact feature 
selection and representation, learning spatiotemporal disease pattern models, and 
generalization of disease models to derive individual tests and provide prospective figures 
for the follow-up of individual patients. This evolution requires the advent of new imaging 
protocols available in clinics and able to provide quantitative information (whereas 
conventional MRI usually provides only qualitative values), new computational models and 
data processing methods able to handle these high dimensional data, and the advent of 
computational infrastructures that will process large datasets in order to foster the statistical 
power of the computational models. 
To match these objectives, we will need to create new clinical-compliant methods for 
quantification of the diffuse inflammation, demyelination and axonal loss particularly from 
molecular/cellular specific imaging and non-conventional MRI. As illustrated on Figure 3, 
this will require to delineate neural circuits and to characterize tissue microstructure present 
in these circuits. There is therefore a need for novel imaging techniques (acquisition and 
processing) to non-invasively characterize alterations in tissue compartments associated with 
disease progression. In addition, the spatial location of lesions with respect to these neural 
circuits likely plays a central role in the progression of disease burden. To address this 
paradox between clinical and MRI observations, new computational solutions will be 
developed in order to better characterize the tissue microstructure from diffusion MRI. We 
need to implement new mathematical models of diffusion imaging able to perform direct 
modelling of the displacement of water molecules under directional diffusion under limited 
scanning time (Stamm et al., 2012) (Hédouin et al., 2015), and able to quantify the diffuse, 
invisible defects of the brain tissues. Similarly, we need to incorporate new relaxometry 
imaging techniques and reconstruction techniques to identify brain tissue compartments. As 
recently stated by the concept of fingerprinting (Ma et al., 2013), normal brain tissue consists 
of tissue compartments that exhibit ranges of T1 and T2 contrast, including myelin-bound 
water, extra-axonal water, and cerebrospinal fluid. There is a pressing need to move from 
voxel level to tissue compartment level measures of disease burden and MS lesion severity. 
Current imaging techniques take too long to identify these compartments for clinical usage, 
and provide poor spatial resolution. However, direct measurement of myelin-bound water, 
	 	 	
Figure 3: Illustration of the diffuse model concept, (left) regular tractography going though MS lesions, (right) 
new diffusion model providing high order diffusion MRI parameters from low angular resolution 
acquisitions  
and other tissue diffusion compartments, will provide critical new insight into lesion burden 
(Stikov et al., 2015). 
Another shift in imaging the MS pathology concerns a better characterization of the 
inflammatory process as it occurs at the early stage. Neuropathological in vitro studies 
suggest that, in active MS lesions at an early or chronic stage (i.e. the “first stage”), the acute 
axonal injury detected by amyloid precursor protein (APP) correlates quantitatively with the 
number of inflammatory cells, especially macrophages (Bitsch et al., 2000), and axonal 
injury is a major substrate for permanent neurological disability in MS patients. This 
knowledge would be important not only for prognostic issues per se, but also – crucially – 
for identifying patients at risk of following a more severe disease course, in order to start 
treating them with more aggressive disease-modifying drugs as early as possible. Imaging 
the neuro-inflammation through cell labeling neuroimaging then becomes crucial for the 
definition of new imaging biomarkers able to exhibit specific signatures such as 
inflammatory cells visible with USPIO, Gd contrast agents on MRI, or with PET signatures 
from dedicated fluorine-18-labeled second-generation TSPO ligands. 
However, one requirement for a large dissemination of these new imaging technologies to 
researchers or clinicians in the clinical neuroscience domain is to set up large-scale studies 
or longitudinal follow-ups involving large samples and several image modalities, time 
points, and acquisition centers. This ambition requires the advent of computational 
infrastructures and shared and advanced image processing methodologies to more efficiently 
compute quantitative parameters from multiple, spatiotemporal imaging sequences. This 
ambition is still a challenge due to the lack of resources and capabilities to locally recruit 
subjects who meet specific inclusion criteria. This motivates the need for sharing the load 
over computational infrastructures in order to produce, store and process the relevant 
imaging data. For these reasons, enabling the pooling of experimental results and processing 
workflows between collaborative centers will allow to recruit large and more specific 
populations of patients; to model and mine new image descriptors from large databases; to 
assimilate a large quantity of imaging data produced on a specific population, and finally to 
amplify scientific results by efficient exploration of multiple computational models tested on 
these distributed experimental study data. 
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